| Physico-chemical condition optimization during biosynthesis lead to development of improved and catalytically efficient gold nano particles M Kumari, A Mishra, S Pandey, SP Singh, V Chaudhry, MKR Mudiam, ... Scientific reports 6 (1), 27575, 2016 | 157 | 2016 |
| FoxO proteins’ nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells S Shukla, F Rizvi, S Raisuddin, P Kakkar Free Radical Biology and Medicine 76, 185-199, 2014 | 87 | 2014 |
| BH3-only protein BIM: an emerging target in chemotherapy S Shukla, S Saxena, BK Singh, P Kakkar European journal of cell biology 96 (8), 728-738, 2017 | 86 | 2017 |
| Essential role of PH domain and leucine-rich repeat protein phosphatase 2 in Nrf2 suppression via modulation of Akt/GSK3β/Fyn kinase axis during oxidative hepatocellular toxicity F Rizvi, S Shukla, P Kakkar Cell death & disease 5 (3), e1153-e1153, 2014 | 76 | 2014 |
| Enhanced cellular internalization: a bactericidal mechanism more relative to biogenic nanoparticles than chemical counterparts M Kumari, S Shukla, S Pandey, VP Giri, A Bhatia, T Tripathi, P Kakkar, ... ACS applied materials & interfaces 9 (5), 4519-4533, 2017 | 73 | 2017 |
| Peptide-based therapeutics: quality specifications, regulatory considerations, and prospects S Rastogi, S Shukla, M Kalaivani, GN Singh Drug discovery today 24 (1), 148-162, 2019 | 69 | 2019 |
| Concurrent acetylation of FoxO1/3a and p53 due to sirtuins inhibition elicit Bim/PUMA mediated mitochondrial dysfunction and apoptosis in berberine-treated HepG2 cells S Shukla, A Sharma, VK Pandey, S Raisuddin, P Kakkar Toxicology and applied pharmacology 291, 70-83, 2016 | 69 | 2016 |
| Implementation of adverse event reporting for medical devices, India S Shukla, M Gupta, S Pandit, M Thomson, A Shivhare, V Kalaiselvan, ... Bulletin of the World Health Organization 98 (3), 206, 2019 | 52 | 2019 |
| Guidance for post-market surveillance and market surveillance of medical devices, including in vitro diagnostics World Health Organization World Health Organization, 2020 | 26 | 2020 |
| Berberine induced modulation of PHLPP2-Akt-MST1 kinase signaling is coupled with mitochondrial impairment and hepatoma cell death S Saxena, S Shukla, P Kakkar Toxicology and Applied Pharmacology 347, 92-103, 2018 | 23 | 2018 |
| Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades … S Rastogi, S Shukla, AK Sharma, M Sarwat, P Srivastava, T Katiyar, ... Toxicology and Applied Pharmacology 395, 114976, 2020 | 12 | 2020 |
| Severe cutaneous adverse reactions in Asians: Trends observed in culprit anti-seizure medicines using VigiBase® S Shukla, S Rastogi, SAH Abdi, P Dhamija, V Kumar, V Kalaiselvan, ... Seizure 91, 332-338, 2021 | 11 | 2021 |
| Morusflavone, a new therapeutic candidate for prostate cancer by CYP17A1 inhibition: exhibited by molecular docking and dynamics simulation SAH Abdi, A Ali, SF Sayed, MJ Ahsan, A Tahir, W Ahmad, S Shukla, A Ali Plants 10 (9), 1912, 2021 | 8 | 2021 |
| Acute intraocular toxicity caused by perfluorocarbon liquids: safety control systems of medical devices GK Srivastava, V Kalaiselvan, C Andrés-Iglesias, S Shukla, R Saxena, ... Graefe's Archive for Clinical and Experimental Ophthalmology 260 (7), 2103-2110, 2022 | 7 | 2022 |
| Clinical and regulatory status of silymarin T Ralli, V Kalaiselvan, R Tiwari, S Shukla, K Kholi Applied Drug Research, Clinical Trials and Regulatory Affairs: Formerly …, 2021 | 7 | 2021 |
| Adverse drug reactions associated with anti-tuberculosis therapy V Kalaiselvan, S Shukla, SR Kumar, N Mishra, P Kumar, RS Raghuvanshi New insights into the future of pharmacoepidemiology and drug safety, 31, 2021 | 6 | 2021 |
| How to improve regulatory practices for refurbished medical devices S Shukla, V Kalaiselvan, RS Raghuvanshi Bulletin of the World Health Organization 101 (6), 412, 2023 | 5 | 2023 |
| Public-private partnership (3Ps) in ensuring safe use of medicines: An Indian experience V Kalaiselvan, S Shukla, S Arora, TP Shrivastava, RS Raghuvanshi Frontiers in Public Health 10, 930696, 2022 | 2 | 2022 |
| New Insights Into the Future of Pharmacoepidemiology and Drug Safety MT Herdeiro, F Roque, TM Silva, A Figueiras BoD–Books on Demand, 2021 | 2 | 2021 |
| Basics and essentials of medical devices safety surveillance V Kalaiselven, S Shukla, N Mishra, P Kumar Magalhães Silva T. New insights into the future of pharmacoepidemiology and …, 2021 | 2 | 2021 |
Dr Poonam KakkarChief Scientist, CSIR-Indian Institute of Toxicology Research, LucknowVerified email at iitr.res.in